Chiu Selina, Staley Helen, Zhang Xiaoxi, Mitra Anita, Sorbi Flavia, Smith James Richard, Yazbek Joseph, Ghaem-Maghami Sadaf, Soni Sanooj, Fotopoulou Christina, Saso Srdjan
Division of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Department of Gynaecology Oncology, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
Cancers (Basel). 2025 Aug 21;17(16):2718. doi: 10.3390/cancers17162718.
Postoperative pain management is complex and crucial in major gynecology oncological surgery. Currently, there is no well-defined standardized approach, resulting in significant variability in practices worldwide. This systematic review evaluates the effectiveness of analgesic strategies used postoperatively in gynecological cancer surgery. A systematic review was conducted from inception to June 26th 2024 to identify all randomized controlled trials (RCTs) assessing pain management following any surgery for gynecological cancer. This was performed on the CENTRAL, PubMed, Embase, and MEDLINE databases. A total of 46 RCTs met the inclusion criteria. Of these 5316 patients, 1844 patients had cervical cancer, 99 had endometrial cancer, and 158 had ovarian cancer. The remaining 3215 participants had unspecified gynecological cancers or benign pathology. No studies focused on postoperative analgesia for vulval cancer. A meta-analysis was not feasible due to heterogeneity in study design, analgesic interventions (i.e., opioids, local anesthetics, paracetamol, NSAIDs, and holistic and complementary therapies), and multiple routes of administration (i.e., oral, parenteral, regional, neuraxial, local infiltration, intraperitoneal, intramuscular, patient-controlled, topical, and rectal). No single analgesic modality demonstrated clear superiority. The median Jadad score for methodological quality of the included trials was 4. The limited cancer-specific RCTs and diversity of analgesia modalities utilized reflect the wide range of applications. Postoperative pain is multifactorial and cannot be adequately managed with a single agent. National and international guidelines should aim to establish a standardized framework for postoperative pain management in gynecological cancers, ensuring accessible, evidence-based care that enhances both short- and long-term patient quality of life.
术后疼痛管理在妇科肿瘤大手术中复杂且至关重要。目前,尚无明确的标准化方法,导致全球范围内的实践存在显著差异。本系统评价评估了妇科癌症手术后使用的镇痛策略的有效性。从开始到2024年6月26日进行了一项系统评价,以识别所有评估妇科癌症手术后疼痛管理的随机对照试验(RCT)。这是在CENTRAL、PubMed、Embase和MEDLINE数据库上进行的。共有46项RCT符合纳入标准。在这5316例患者中,1844例患有宫颈癌,99例患有子宫内膜癌,158例患有卵巢癌。其余3215名参与者患有未明确的妇科癌症或良性病变。没有研究关注外阴癌的术后镇痛。由于研究设计、镇痛干预措施(即阿片类药物、局部麻醉药、对乙酰氨基酚、非甾体抗炎药以及整体和补充疗法)以及多种给药途径(即口服、胃肠外、区域、神经轴、局部浸润、腹腔内、肌肉内、患者自控、局部和直肠)存在异质性,因此无法进行荟萃分析。没有单一的镇痛方式显示出明显的优越性。纳入试验的方法学质量的Jadad评分中位数为4。有限的癌症特异性RCT和所采用的镇痛方式的多样性反映了广泛的应用范围。术后疼痛是多因素的,无法用单一药物充分管理。国家和国际指南应旨在建立妇科癌症术后疼痛管理的标准化框架,确保提供可及的、基于证据的护理,以提高患者的短期和长期生活质量。